Vitamin D (200 000 IU) for the Treatment of Painful Diabetic Neuropathy
Overview
- Phase
- Not Applicable
- Intervention
- Cholecalciferol
- Conditions
- Painful Diabetic Neuropathy
- Sponsor
- Baqai Institute of Diabetology and Endocrinology
- Enrollment
- 216
- Locations
- 1
- Primary Endpoint
- Change from baseline in DN4 score.
- Last Updated
- 3 years ago
Overview
Brief Summary
The main objective of this study is to evaluate the effect of vitamin D3 on diabetic individual with painful neuropathy in a tertiary healthcare.
The people with diabetes (type 1 and type 2) who have a Douleur Neuropathique 4 (DN4) score ≥4 will be considered eligible in this prospective study. Their serum samples will be subjected to pre-and post-biochemical screening of serum 25 (OH) D and HbA1c. The individual having Vitamin D insufficiency and deficiency will be administered a single dose of oral Vitamin D3 (Soft Gel capsule 200,000 IU), and follow-up for post-biochemical screening after 3 months.
Detailed Description
Painful diabetic neuropathy (PDN) is the most common diabetic complication in patients who have had diabetes mellitus for a long time. Diabetic peripheral neuropathy is the common cause of neuropathy globally. About 50-60% of individuals with long-term diabetes develop diabetic neuropathy. Several recent observational studies in diabetic individuals have provided a correlation between vitamin D insufficiency and diabetes. Despite the fact that the pathogenesis of diabetic neuropathy is complex, recent investigations revealed that deficiency of vitamin D is an important factor in the development of diabetic neuropathy. Also, vitamin D supplementation was found to be effective in treating neuropathic pain and preventing neuronal degeneration. Aims and Objectives: The assessment of the effect of single-dose, oral vitamin D in patients with painful diabetic neuropathy. Materials and Methods: Study Drug: Oral cholecalciferol (Vitamin D3 capsule 200,000 IU). A single oral dose of 200000 IU vitamin D will be administered in people with diabetic neuropathy, and the effect will be observed after 3 months. * Sample size = 216 type 1 and 2 diabetic subjects * Recruitment time = 4 months * Treatment duration = 3 months Ethical Approval: The ethical approval for this study will be taken from the Institutional Review Board (IRB) of Baqai Institute of Diabetology and Endocrinology (BIDE) Study Area and Duration: This study is going to be conducted from October 2021 to March 2022 in the outpatient department (OPD) of BIDE. Data Analysis and Statistics: The primary analysis will compare the change from baseline. Comparisons within each treatment group across time will also be considered. The analysis will be performed with the Statistical Package for the Social Sciences (SPSS). Assessment during the Treatment Period: * Change from baseline in DN4 * Change from baseline in serum 25 (OH) D, * Change from baseline in HbA1c
Investigators
Abdul Basit
Professor of Medicine, and Director
Baqai Institute of Diabetology and Endocrinology
Eligibility Criteria
Inclusion Criteria
- •Insulin dependent diabetes
- •Insulin independent diabetes
- •Age range between 25 to 80 years
- •Glycated hemoglobin (HbA1c) level must be ≥ 6.5%
- •Apparently no symptoms of Vitamin D Deficiency
Exclusion Criteria
- •History of hyperparathyroidism
- •Pregnant women
- •Lactating mothers
- •History for rickets and osteomalacia
- •On Vitamin D supplementation
- •On Multivitamin
- •On anti-epileptics
- •On steroids
- •On bisphosphonates
- •On oral contraceptives
Arms & Interventions
2. Insufficient Vit D (20-30ng/mL)
single oral dose capsule 200,000 IU of Cholecalciferol
Intervention: Cholecalciferol
4. Deficient Vit D
single oral dose capsule 200,000 IU of Cholecalciferol
Intervention: Cholecalciferol
Outcomes
Primary Outcomes
Change from baseline in DN4 score.
Time Frame: 3 months
The change will be observed with the help of neuropathic pain assessment questionnaire.
Change from baseline in serum HbA1c.
Time Frame: 3 months
The change will be observed in the serum values of glycated hemoglobin at the end point after the administration of vitamin D.
Change from baseline in serum vitamin D.
Time Frame: 3 months
The cholecalciferol (Vitamin D) level in serum will be observed at the end point after the administration of vitamin D.